ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Jean-Noel Fabiani
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grinda, J.-M.
Right arrow Articles by Fabiani, J.-N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grinda, J.-M.
Right arrow Articles by Fabiani, J.-N.
Related Collections
Right arrow Mechanical Circulatory Assistance

Ann Thorac Surg 2005;80:945-948
© 2005 The Society of Thoracic Surgeons

Original article: Cardiovascular

Human Leukocyte Antigen Sensitization in Ventricular Assist Device Recipients: A Lesser Risk With the DeBakey Axial Pump

Jean-Michel Grinda, MD a , * , Marie-Odile Bricourt, MD a , Catherine Amrein, MD a , Suzanne Salvi, MD a , Romain Guillemain, MD a , Anne Francois, MD b , Pierre Guibourt, MD a , Alain Deloche, MD a , Jean-Noel Fabiani, MD a

a Department of Cardiovascular Surgery and Thoracic Transplantation, Hôpital Européen Georges Pompidou, Paris, France
b Blood Bank, Hôpital Européen Georges Pompidou, Paris, France

Accepted for publication March 23, 2005.

* Address reprint requests to Dr Grinda, Cardiac Surgery Department, Hôpital Europeen Georges Pompidou, 21 rue Leblanc, 75908, Paris cedex 15, France; (Email: jean-michel.grinda{at}egp.ap-hop-paris.f).

BACKGROUND: Previous reports, all concerning pulsatile devices, have indicated an increased risk of development of circulating antileukocyte antigen (HLA; human leukocyte antigen) antibodies during ventricular assist device (VAD) support. We investigated sensitization in patients implanted with the DeBakey VAD (MicroMed Technology, Inc, Houston, TX) axial flow pump as a bridge to heart transplantation.

METHODS: Inclusion criteria for this prospective study were the following. Patients implanted with the DeBakey VAD axial flow pump, without HLA antibodies prior to implantation, with a duration of support of at least one month. The HLA antibody testing for IgG and IgM class I and II antibodies was performed weekly during support, using both a complement dependant cytotoxicity assay and an enzyme-linked immunosorbent assay (ELISA). Retrospective cross match was performed for all patients transplanted. The occurrence of graft rejection was determined by regular endomyocardial biopsies after heart transplantation, graded according to the International Society for Heart and Lung Transplantation (ISHLT) guidelines. Additionally, the transfusion history was reviewed for all patients.

RESULTS: Fourteen patients were included representing 1,220 cumulative patient-days of support (mean duration time on support, 87 days). No patient developed detectable IgG antibodies to class I or II. One patient had a positive ELISA, corresponding to nonsignificant (6/30) class I IgM antibodies at 3 weeks postimplantation. Ten patients underwent successful heart transplantation, representing 156 cumulative months. No retrospective cross match was positive. The percentage of significant acute rejection episodes (ISHLT grade 3A or more) was 6% and 4.3% in the first 6 months and from 6 to 12 months, respectively. No vascular rejection was noted. The posttransplantation survival rate was 87% at 6 months and 75% at 1 year, respectively.

CONCLUSIONS: Patients implanted with the DeBakey VAD axial flow pump as a bridge to heart transplantation do not appear to be exposed to an increased risk of sensitization.




This article has been cited by other articles:


Home page
 J. Thorac. Cardiovasc. Surg.Home page
I. George, P. Colley, M. J. Russo, T. P. Martens, E. Burke, M. C. Oz, M. C. Deng, D. M. Mancini, and Y. Naka
Association of device surface and biomaterials with immunologic sensitization after mechanical support.
J. Thorac. Cardiovasc. Surg., June 1, 2008; 135(6): 1372 - 1379.e1.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
S. Klotz, J. Stypmann, H. Welp, C. Schmid, G. Drees, A. Rukosujew, and H. H. Scheld
Does Continuous Flow Left Ventricular Assist Device Technology Have a Positive Impact on Outcome Pretransplant and Posttransplant?
Ann. Thorac. Surg., November 1, 2006; 82(5): 1774 - 1778.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
H. J. Ankersmit, B. Moser, and E. Wolner
Invited commentary.
Ann. Thorac. Surg., September 1, 2006; 82(3): 893 - 894.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
W. L. Holman
Invited commentary
Ann. Thorac. Surg., September 1, 2005; 80(3): 948 - 949.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2005 by The Society of Thoracic Surgeons.